PathoVax

PathoVax is a new biotechnology company seeking to eradicate HPV disease and cancers. Join us in "Blazing the trail to complete protection"

PathoVax LLC is developing breakthrough vaccines against infectious diseases and cancers utilizing a Human Papillomavirus Virus-Like Particle (HPV VLP) platform that has been exclusively licensed from the Johns Hopkins University. This technology is generated by the same investigators responsible for existing HPV vaccines, and can be used to present other antigens to induce robust humoral or cellu

lar immune responses against multiple infectious agents and tumors. Our lead candidate (RGVax™) is a patented, universal HPV vaccine that targets all clinically-relevant HPVs while sidestepping uptake challenges to more than double a global market with over $2B in annual revenues

Here at PathoVax, we are blazing the trail to complete protection. Disclaimer: The information contained in these posts is not intended or implied to be a substitute for professional medical advice and is provided for educational purposes only. Readers are to seek full responsibility on how to use this information. Always seek the advice of a physician or medical professional before starting any new treatment or discontinuing any existing treatment. Readers are to talk to their healthcare provider about any questions they may have regarding their medical condition. Nothing contained in these topics is intended to be used for medical diagnosis or treatment, nor should it be used as a substitute for the care and knowledge your physician may/can provide you.

05/14/2019

PathoVax LLC is pleased to have a presence back in Boston as part of the family at . We are also very pleased to be alongside fellow Singaporean Company 🇸🇬🇺🇸

03/12/2019

Two pieces of great news this Mid-March! First off, PathoVax has secured another SBIR Phase 1 worth $300K from the NCI to imbue thermostable and single-dose properties into our existing RGVax HPV vaccine. This new formulation will potentiate the world’s 1st single- immunization, thermostable, broad-spectrum Human Papillomavirus (HPV) Vaccine!!

Secondly, We will be presenting long term pre-clinical protection data in a Late Breaking Abstract Poster session at the upcoming 2019 American Association for Cancer Research Annual Meeting!!!

12/21/2018

1st Annual PathoVax Christmas Party! Special thanks to our Scientific Advisor, Prof Roden for joining us!!! ! Happy Holidays to all!!!

10/19/2018

PathoVax closes $2.75M Series A1 round!

The company is working toward clinical trials of its HPV vaccine.

09/20/2018

UPDATE: Catch all our talks/posters at the IPVC conference! .

4th Oct 1300-1400, Exhibition Area, Session code: PS10
Speaker: Prof Reinhard Kirnbauer, Scientific Advisor, Inventor of RGVax
Title: THERMOSTABILIZATION OF RG1-VLPS, A BROAD-SPECTRUM HPV VACCINE CANDIDATE

4th Oct, 15:45, Room C4.9, Session code: RC02
Speaker: Joshua Wang, Co-Founder
Presentation Title: cGMP PRODUCTION OF A MONOVALENT CHIMERIC PAPILLOMAVIRUS VACCINE (HPV16 RG-1VLP) CONFERS CROSS PROTECTION AGAINST DISEASE EQUIVALENT TO TYPE-SPECIFIC LICENSED L1-VLP VACCINES IN PAPILLOMAVIRUS ANIMAL MODELS

6th October, 12:35, Room C4.9, Session code: SSS07
Speaker: Prof Richard Roden, Scientific Advisor, Inventor of RGVax
Presentation Title: ROLES OF FC DOMAIN AND EXUDATION IN L2 ANTIBODY-MEDIATED PROTECTION AGAINST HUMAN PAPILLOMAVIRUS

===============
PathoVax's late-breaking abstract has been accepted for an ORAL PRESENTATION during the 32nd International Papillomavirus Conference held at Sydney, Australia from October 2-6, 2018.

Looking forward to presenting our RGVax vaccine data demonstrating complete cross-protection against several HPVs!

Join us at IPVC for an outstanding program of invited lectures, oral abstract sessions, poster sessions, symposia, workshops and social events in magical Sydney!

07/30/2018

Expanding our global outreach! We are pleased to announce that PathoVax is a 2018 Laureate in the YEi initiative program. This provides a personalized immersion week in France (including training sessions, networking and one-on-one meetings) that will allow us to benefit from an extensive customized business network and connections to the best resources in Europe.

The YEi Start in France program is an annual competition organized by the Ministry for Europe and Foreign Affairs for young foreign science-based companies interested in growing their business in France and Europe. Meet the 2018 US Laureates of the YEI Start in France Program.

07/04/2018

Happy 4th of July! As fireworks light up the sky to celebrate Independence Day! We are celebrating our own brand new independent lab space !

06/09/2018

In addition to the US$30k First Place prize award, PathoVax received a fully-sponsored networking trip to six major cities in China (Beijing, Shandong, Shanghai, Hefei, Hangzhou and Guangzhou) from July-20 to August-5. Get in touch if you are interested to learn more about the first universal HPV vaccine!

BOSTON, June 6, 2018 /PRNewswire/ -- On April 22, 2018, the 4th annual China-US Innovation Competition hosted by...

03/21/2018

We are honored to have received 1st Place ($100K RMB) at the 2nd China (Shenzhen) Innovation & Entrepreneurship International Competition (Boston, USA division)! Looking forward to having Weijie Poh represent us and share our vision of preventing and treating Cancers/infectious diseases at the grand finals in Shenzhen, China! #全面保护 #加油!!!!

01/26/2018

Today marks the last day of our tenure as alum-in-residence at the Harvard Innovation Labs. Thanks for housing us during our early days in Boston and accelerating our growth in this amazing ecosystem!

01/02/2018

Proud feature in the Baltimore Business Journal. We hope to bring this positive momentum into 2018!

updated with article link! http://bizj.us/1phbiq

The grants came through the National Institute of Allergy and Infectious Diseases and the National Science Foundation.

12/20/2017

Christmas comes early for PathoVax this year!

Following our STTR award in September by the National Cancer Institute (NCI), we are pleased to announce that PathoVax has been awarded TWO more SBIR grants ($2.3M USD in total) from the National Institute of Allergy and Infectious Diseases (NIAID) as well as the National Science Foundation (NSF) to advance our Human Papillomavirus Virus-like particles for both infectious diseases and cancer!!

These grants will fund activities associated with filing an Investigational New Drug (IND) application with the FDA for PathoVax's lead product candidate as well as continue our research in using our HPV VLPs for therapeutic purposes!

Address

Baltimore, MD

Website

http://www.pathovax.com/

Alerts

Be the first to know and let us send you an email when PathoVax posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your business to be the top-listed Business in Baltimore?